Key Insights

Highlights

Success Rate

96% trial completion (above average)

Published Results

20 trials with published results (22%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

2.2%

2 terminated out of 92 trials

Success Rate

95.9%

+9.4% vs benchmark

Late-Stage Pipeline

33%

30 trials in Phase 3/4

Results Transparency

43%

20 of 47 completed with results

Key Signals

20 with results96% success

Data Visualizations

Phase Distribution

70Total
Not Applicable (23)
Early P 1 (1)
P 1 (5)
P 2 (11)
P 3 (19)
P 4 (11)

Trial Status

Completed47
Unknown14
Recruiting12
Active Not Recruiting9
Withdrawn4
Not Yet Recruiting3

Trial Success Rate

95.9%

Benchmark: 86.5%

Based on 47 completed trials

Clinical Trials (92)

Showing 20 of 20 trials
NCT07034690Phase 4RecruitingPrimary

Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia

NCT05485961Phase 2RecruitingPrimary

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

NCT03705234Phase 3Active Not RecruitingPrimary

A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease

NCT07203677Completed

Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT)

NCT07037433Phase 3RecruitingPrimary

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

NCT07551492Phase 3Not Yet RecruitingPrimary

A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease

NCT05355402Phase 2Completed

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

NCT07543731Not Yet Recruiting

A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab

NCT05030428Phase 3Active Not RecruitingPrimary

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

NCT06875973Phase 3RecruitingPrimary

Pelacarsen Roll-over Extension Program

NCT06112327Enrolling By InvitationPrimary

Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease

NCT05726838Active Not RecruitingPrimary

The Belgian REAL (BE.REAL) Registry

NCT05581303Phase 3Active Not RecruitingPrimary

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

NCT06813339Early Phase 1RecruitingPrimary

Placebo-controlled Study of Single and Multiple Ascending Doses of UDP-003 in Healthy Human Participants and Patients

NCT06692764Phase 2CompletedPrimary

A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure

NCT07160829CompletedPrimary

Focus on Levels of Awareness and Perceptions Regarding hsCRP in Identifying Systemic Inflammation in ASCVD, CKD and Heart Failure Management

NCT05977413Not ApplicableWithdrawnPrimary

NOTIFY (New Observations Taking Information From Yesterday)

NCT05749874Phase 4Active Not Recruiting

Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus

NCT06424860Phase 1Recruiting

Fish Oil, Metformin and Heart Health in PCOS

NCT06675175Phase 1Completed

A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.

Scroll to load more

Research Network

Activity Timeline